BridgeBio Pharma (BBIO) Asset Writedowns and Impairment (2021 - 2022)
BridgeBio Pharma (BBIO) posted Asset Writedowns and Impairment of $67000.0 for Q3 2022, down 99.47% sequentially from $12.7 million in Q1 2022.
Powered by 
Analysis
BridgeBio Pharma (BBIO) Asset Writedowns and Impairment (2021 - 2022) Analysis & Trends
BridgeBio Pharma has reported Asset Writedowns and Impairment for 2 years, with the latest figure at $67000.0 in Q3 2022.
- Quarterly Asset Writedowns and Impairment changed N/A year-over-year to $67000.0 in Q3 2022, while the trailing twelve-month figure through Jun 2023 was $67000.0 (down 99.28% YoY) and the FY2024 annual result came in at $271000.0, changed N/A from the prior year.
- Asset Writedowns and Impairment declined to $67000.0 in Q3 2022 per BBIO's latest filing, from $12.7 million in the prior quarter.
- Over five years, Asset Writedowns and Impairment peaked at $12.7 million in Q1 2022 and troughed at -$3.3 million in Q4 2021.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn |
| 10 | BridgeBio Pharma | 14.65 Bn | 13.93 Bn | 228.63 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Sep 30, 2022 | 67,000.00 |
| Mar 31, 2022 | 12.65 Mn |
| Dec 31, 2021 | -3.30 Mn |
| Mar 31, 2021 | 3.30 Mn |